Evidence map›Paper›PMID 25402616›Full record

ArticleNature biotechnology2014

Tunable protein degradation in bacteria.

D Ewen Cameron, James J Collins

Open access · greenAbstract read
In one paragraph

Article in Nature biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 276 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Oligonucleotide genetics forbioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Protein overabundance is driven by growth robustness.bioRxiv : the preprint server for biology · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Colony pattern multistability emerges from a bistable switch.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

D Ewen Cameron1] Howard Hughes Medical Institute, Boston University, Boston, Massachusetts, USA. [2] Center of Synthetic Biology, Boston University, Boston, Massachusetts, USA. [3] Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA.
James J Collins1] Howard Hughes Medical Institute, Boston University, Boston, Massachusetts, USA. [2] Center of Synthetic Biology, Boston University, Boston, Massachusetts, USA. [3] Department of Biomedical Engineering, Boston University, Boston, Massachusetts, USA. [4] Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts, USA.
Boston University · USHoward Hughes Medical Institute · US

Funding

A Network Biology Approach to Antibiotic Action and Bacterial Defense MechanismsDP1OD003644 · OD · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLLINS, JAMES J · 2007 to 2011
$4.1M
Howard Hughes Medical InstituteNIH HHS DP1 OD003644
6 · The paper itself

Abstract

Tunable control of protein degradation in bacteria would provide a powerful research tool. Here we use components of the Mesoplasma florum transfer-messenger RNA system to create a synthetic degradation system that provides both independent control of steady-state protein level and inducible degradation of targeted proteins in Escherichia coli. We demonstrate application of this system in synthetic circuit development and control of core bacterial processes and antibacterial targets, and we transfer the system to Lactococcus lactis to establish its broad functionality in bacteria. We create a 238-member library of tagged essential proteins in E. coli that can serve as both a research tool to study essential gene function and an applied system for antibiotic discovery. Our synthetic protein degradation system is modular, does not require disruption of host systems and can be transferred to diverse bacteria with minimal modification.

Indexed as

ProteolysisEntomoplasmataceaeEscherichia coliGene Expression Regulation, BacterialLactococcus lactisMolecular Sequence DataRNA, MessengerRNA, Messenger

Identifiers

PMID25402616
PMCPMC4262603
OpenAlexW1965305472

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.